<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thalidomide acts on the microenvironment of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) by influencing cytokine networks, and growing evidence supports thalidomide's usefulness in the management of <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e>, such as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The European Collaboration Group on <z:hpo ids='HP_0011974'>Myelofibrosis</z:hpo> with <z:mpath ids='MPATH_173'>Myeloid Metaplasia</z:mpath> reviewed patients who received at least four weeks' thalidomide treatment, in doses ranging from 50 mg/day to 400 mg/day </plain></SENT>
<SENT sid="2" pm="."><plain>The results showed that 30% of patients had increases in <z:chebi fb="34" ids="35143">haemoglobin</z:chebi>, and, of these, almost 40% became transfusion independent </plain></SENT>
<SENT sid="3" pm="."><plain>Platelets were increased in a significant proportion of patients, and approximately 40% of patients had a reduction in their spleen size </plain></SENT>
<SENT sid="4" pm="."><plain>Data on thalidomide and <z:hpo ids='HP_0011009'>acute</z:hpo> myeloblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) are conflicting: a recently published study indicated that thalidomide does not have a role in the management of <z:hpo ids='HP_0011009'>acute</z:hpo> myeloblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), while other studies suggest some patients may respond because of thalidomide's ability to activate natural killer cells and cytotoxic T-lymphocytes </plain></SENT>
<SENT sid="5" pm="."><plain>Partial responses to thalidomide treatment have been recorded in patients with <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>In a phase II study to assess the activity of thalidomide in patients with <z:e sem="disease" ids="C0024419" disease_type="Neoplastic Process" abbrv="">Waldenstrom's macroglobulinaemia</z:e>, a partial response was seen in 25% of patients who received a starting dose of 200 mg, which was escalated in 200 mg increments every 14 days as tolerated to a maximum of 600 mg </plain></SENT>
<SENT sid="7" pm="."><plain>Although further study is required, thalidomide shows promise in the treatment of a number of <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e>, many of which currently have limited treatment options and poor prognosis </plain></SENT>
</text></document>